Epynext Therapeutics develop a new generation of monoclonal antibodies targeting mutli-resistant bacterias.

• A web-based platform to facilitate patients journeys and therapeutic education in severe chronic diseases.• First digital cohort of nephrology patients in France, 12 major hospital units involved.• Secured funding from the French Ministry of Health. • Relationships with private investors, winner of several start-ups awards.

Consulting and transformation projects lead-For an early-stage biotech: business planning and development, communication and dossier preparation for investors and public funding bank.-For an immuno-oncology biotech (Euronext): scientific and economic intelligence, marketing strategy, investors & industrial partners communication.- For a big pharmaceutical: strategic planning of a major launch in diabetes.-Various 3 months to 3 years projects for big pharmaceuticals: business planning, business excellence, international project management.-Mentor and expert for EIT Health and MIT Hacking Medicine networks.

Sales of 150M$, 75 people.Coordinating brand teams across the region.Regional KOLs management.Strategic recommendation following Pfizer's acquisition.

Sales of 20M$, 15 peopleSetting up of a new operational organization, definition of the new activity and performance monitoring tools.Member of the Global Transplant Leadership Team and of the European brand management team.

Reporting into the EMEA President and the EMEA Operational Committee.Definition and implementation of key strategic projects across European affiliates: eMarketing, eLearning and intranet.More than 50 sites and applications implemented across Europe including DTC web sites.

Management of International assignments at board level. Conception, presentation and successful sale of proposals to GlaxoWellcome, Jefferson Smurfit Group, MSD, Orion Pharma, Renault-Nissan.

Sales manager, north of France, 150 reps.First area in sales, growth and market share in 1998.

District manager, France, 10 reps.Fastest growing district in 1994 and 1995.

International launch of a new ACE inhibitor, highest promotional budget of the company at that time.

Management of a marketing team in the areas of arthritis, analgesics, rheumatoid arthritis and osteoporosis.